MRVI vs. ELAN, ROIV, INSM, ASND, CERE, LEGN, ITCI, VKTX, JAZZ, and SMMT
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry.
Maravai LifeSciences (NASDAQ:MRVI) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Maravai LifeSciences presently has a consensus target price of $11.44, suggesting a potential upside of 32.92%. Elanco Animal Health has a consensus target price of $18.29, suggesting a potential upside of 0.42%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Elanco Animal Health.
Maravai LifeSciences has higher earnings, but lower revenue than Elanco Animal Health. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Elanco Animal Health had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 12 mentions for Elanco Animal Health and 2 mentions for Maravai LifeSciences. Elanco Animal Health's average media sentiment score of 1.01 beat Maravai LifeSciences' score of 0.98 indicating that Elanco Animal Health is being referred to more favorably in the news media.
Elanco Animal Health received 73 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. However, 67.44% of users gave Maravai LifeSciences an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.6% of Maravai LifeSciences shares are held by insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Maravai LifeSciences has a beta of 0.06, suggesting that its share price is 94% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.
Elanco Animal Health has a net margin of -29.83% compared to Maravai LifeSciences' net margin of -47.81%. Elanco Animal Health's return on equity of 5.98% beat Maravai LifeSciences' return on equity.
Summary
Elanco Animal Health beats Maravai LifeSciences on 10 of the 18 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
